Seed Therapeutics is developing molecular glues to degrade disease-causing proteins. Targeted protein degradation is a cellular mechanism that enables specific proteins to be destroyed through the use of ubiquitin E3 ligases. E3 ligases provide specificity by recognising chains of ubiquitin marks on proteins. Seed is exploiting this mechanism to reduce the amount of disease-causing proteins - such as oncogenes - that are frequently overexpressed or over-activated in cancer. To achieve this, Seed is using their understanding of “molecular glues” to induce ubiquitin E3 ligases to bind dysfunctional proteins that it normally would not. Currently, Seed is focusing on neurodegeneration and cancer targets, including the oncogene KRAS.

<p>Seed Therapeutics is developing molecular glues to degrade disease-causing proteins. Targeted protein degradation is a cellular mechanism that enables specific proteins to be destroyed through the use of ubiquitin E3 ligases. E3 ligases provide specificity by recognising chains of ubiquitin marks on proteins. Seed is exploiting this mechanism to reduce the amount of disease-causing proteins - such as oncogenes - that are frequently overexpressed or over-activated in cancer. To achieve this, Seed is using their understanding of “molecular glues” to induce ubiquitin E3 ligases to bind dysfunctional proteins that it normally would not. Currently, Seed is focusing on neurodegeneration and cancer targets, including the oncogene KRAS.</p>


Seed Therapeutics

Company info:

About company:

Jobs: